ClinicalTrials.gg
CompletedNCT01343511Updated Oct 14, 2011

Safety and Efficacy of Stem Cell Therapy in Patients With Autism

A Phase 1/2 interventional study of human cord blood mononuclear cells and human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells in Autism, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2011-10-14.

Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Autistic Disorder with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Autistic Disorder · China.

Enrollment
16th of 20
37 · median 66
Started
2009
the only one that year
Phase 1/2
2 of 26
1 open now
Registered
1st of 26
by date

Among the 26 studies in Autistic Disorder with a site in China, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 1st registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

13 of the 26 studies in Autistic Disorder with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Autistic Disorder with a site in China, or all of them as a file.
02

Study summary

Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic effect of current treatments remains limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy. In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be evaluated in patients with Autism.

Read the detailed description

To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Autism.

03

Conditions studied

  • Autism

Browse trials for

Keywords

  • Autism
  • human cord blood mononuclear cells
  • human umbilical cord mesenchymal stem cells
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children between the ages of 3 and 12 years.
  • diagnosis of Autistic Disorder.
  • Total score of CARS ≥ 30.
  • Parents or legal guardian willing to sign the ICF.

Exclusion criteria

Exclusion Criteria:

  • Any history of to serum products, or other known drug and food allergy.
  • History of prior or current psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's.
  • History of Epileptic seizure activity in the past 6 months.
  • Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.
  • The global autism ratings are assessed as being absent, minimal or mild.
  • Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive dyskinesia.
  • Subjects who have displayed significant self-injurious behavior (children who have caused visible harm to themselves).
  • +
  • Acute and chronic hepatitis.
  • disease, e.g. lupus erythematosus, multiple sclerosis.
  • Severe pulmonary and hematological disease, or hypo-immunity.
  • Currently undertaking other treatment that may affect the safety/efficacy of stem cells.
  • Enrollment in other trials in the last 3 months.
  • Other criteria the investigator consider improper for inclusion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Rehabilitation plus hCB-MNCs treatment

    Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.

    Biological: human cord blood mononuclear cells

  • Experimental
    Rehabilitation plus hCB-MNCs and hUC-MSCs therapy

    Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.

    Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells

Interventions

  • Biologicalhuman cord blood mononuclear cells

    Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.

    Also known as: Group 1

  • Biologicalhuman cord blood mononuclear cells and human umbilical cord mesenchymal stem cells

    Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.

    Also known as: Group 2

06

What researchers measure

Primary outcomes

  1. Childhood Autism Rating Scale,CARS

    Time frame: 6 months after treatment

  2. Clinical Global Impression Scale,CGI

    Time frame: 6 months after treatment

Secondary outcomes

  1. Aberrant Behavior Checklist,ABC

    Time frame: 6 months after treatment

  2. Adverse Event and Serious Adverse Event

    Time frame: 6 months after treatment

07

Study locations

1 site
  • Shandong Jiaotong Hospital
    Jinan, Shandong 250031, China
08

References and documents

Publications

  • Liu M, Sun LW, LV YT, Huan Y, Ge RC, Cao YL, Guo CQ, Chen XW. Stem cells for treatment of autism: Safety and efficacy. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(32): 5967-5970.
  • Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, Huan Y, Ge RC, Chen XW, Wang ZJ, Kim BJ, Hu X. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013 Aug 27;11:196. doi: 10.1186/1479-5876-11-196. PubMed 23978163 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2011
First posted
Apr 28, 2011
Start
Mar 2009
Primary completionActual
Jun 2010
CompletionActual
May 2011
Last update
Oct 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01343511
Lead sponsor
Shenzhen Beike Bio-Technology Co., Ltd.
Collaborators
Shandong Jiaotong Hospital, Association for the Handicapped Of Jinan
Responsible party
Sponsor
First posted
Apr 28, 2011
Start date
Mar 2009
Primary completion
Jun 2010
Completion
May 2011
Last update
Oct 14, 2011

Study contacts

Yongtao Lv
principal investigator · Shandong Jiaotong Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion